Isotonische Kochsalzlösung Fresenius

DRUG4 trials

Sponsors

Moderna Therapeutics Inc., Alvotech Swiss AG, Universitaetsklinikum Tuebingen AöR, Friedrich-Schiller-Universitaet Jena, Friedrich-Schiller-Universitaet Jena

Conditions

Diagnosis of chronic depressionGlycogen storage disease type 1a (GSD1a)Moderate to Severe Active Ulcerative ColitisPatients with sepsis or septic shockcurrently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed.

Phase 1

A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension

CompletedCTIS2022-502963-39-00

Moderna Therapeutics Inc.Glycogen storage disease type 1a (GSD1a)

Start: 2024-06-20End: 2025-10-06Target: 24Updated: 2025-07-30

Phase 2

Pharmacologic treatment augmentation in chronic depression “randomized, controlled, double blinded, phase II study”

RecruitingCTIS2024-512478-86-00

Universitaetsklinikum Tuebingen AöRDiagnosis of chronic depression

Start: 2023-07-07Target: 60Updated: 2024-04-10

Epirubicin for the Treatment of Sepsis & Septic Shock

CompletedCTIS2024-515776-12-00

Friedrich-Schiller-Universitaet Jena, Friedrich-Schiller-Universitaet Jenacurrently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed., Patients with sepsis or septic shock

Start: 2022-06-30End: 2025-05-21Target: 45Updated: 2024-10-01

Phase 3

A Parallel-Group Treatment, Double-Blind, 2-Arm Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects Aged 18 to 80 Years Inclusive with Moderate to Severe Active Ulcerative Colitis

CompletedCTIS2023-507705-34-00

Alvotech Swiss AGModerate to Severe Active Ulcerative Colitis

Start: 2025-08-29End: 2025-10-14Target: 462Updated: 2025-02-05